Industry News Archives | International Rett Syndrome Foundation

November 6, 2025

Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome

Filter

Neurogene

Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates

UCB

UCB Pharma to initiate phase 3 clinical trial of fenfluramine to treat Rett syndrome

Neurogene

Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome (Community Letter)

Neurogene

Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome

Taysha

Taysha Gene Therapies Updates on Part A Data, Plans for the Part B Pivotal Study, and FAQs (Community Letter)

Neurogene

Neurogene Updates on Program & Risk Mitigation Strategies (Community Letter)

Taysha

Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102

Acadia

Acadia Pharmaceuticals Announces Recipients of Second Annual Rett Sibling Scholarship

Taysha

Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update